FY2025 · period end Dec '25 · from the 10-K filed Feb 26, 2026
Data as filed with the SEC, provided for information only — not investment advice.
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Revenue | $6.52B | $6.13B | $5.58B | $5.02B | $4.69B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $4.23B | $3.93B | $3.44B | $3.02B | $2.65B |
| Net Income | $4.07B | $3.53B | $3.23B | $2.69B | $2.64B |
| EPS (Diluted) | $11.16 | $9.67 | $8.86 | $7.40 | $7.29 |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Total Assets | $198.42B | $137.45B | $129.71B | $174.18B | $196.78B |
| Total Liabilities | $169.70B | $110.96B | $102.97B | $147.30B | $169.38B |
| Stockholders' Equity | $28.73B | $26.49B | $26.74B | $26.88B | $27.40B |
| Cash & Equivalents | $4.42B | $2.89B | $2.91B | $2.72B | $2.83B |
| Total Debt | — | — | — | — | — |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Operating Cash Flow | $4.28B | $3.69B | $3.45B | $3.06B | $2.40B |
| Capital Expenditures | $0.08B | $0.09B | $0.08B | $0.09B | $0.13B |
| Free Cash Flow | $4.19B | $3.60B | $3.38B | $2.97B | $2.28B |
| Metric | FY25Dec '25 | FY24Dec '24 | FY23Dec '23 | FY22Dec '22 | FY21Dec '21 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | 0.6% | 0.6% | 0.6% | 0.6% | 56.4% |
| Net Margin | 0.6% | 0.6% | 0.6% | 0.5% | 56.2% |
| Return on Equity | 14.8% | 13.2% | 12.0% | 9.9% | 9.6% |
| Return on Assets | 2.4% | 2.6% | 2.1% | 1.5% | 1.3% |
| Debt / Equity | — | 0.03× | — | 0.00× | — |
Showing the most recent 5 annual periods. Get 15 years of history on the Pro plan, or full history back to 1993 plus the smart-money dataset and webhooks on Institutional.
| Form | Accession ID | Report Date | Filing Date | Accepted At | Source |
|---|---|---|---|---|---|
| 10-Q | 0001156375-26-000047 | Jun 30, 2026 | Jul 24, 2026 | Jul 24, 2026 18:43 UTC | EDGAR |
| 10-Q | 0001156375-26-000020 | Mar 31, 2026 | Apr 24, 2026 | Apr 24, 2026 18:38 UTC | EDGAR |
| 10-K | 0001156375-26-000009 | Dec 31, 2025 | Feb 26, 2026 | Feb 26, 2026 22:30 UTC | EDGAR |
| 10-Q | 0001156375-25-000206 | Sep 30, 2025 | Oct 24, 2025 | Oct 24, 2025 18:07 UTC | EDGAR |
| 10-Q | 0001156375-25-000182 | Jun 30, 2025 | Jul 25, 2025 | Jul 25, 2025 00:01 UTC | EDGAR |
| 10-Q | 0001156375-25-000103 | Mar 31, 2025 | Apr 30, 2025 | Apr 30, 2025 18:50 UTC | EDGAR |
| 10-K | 0001156375-25-000021 | Dec 31, 2024 | Feb 27, 2025 | Feb 27, 2025 21:30 UTC | EDGAR |
| 10-Q | 0001156375-24-000200 | Sep 30, 2024 | Nov 8, 2024 | Nov 8, 2024 20:23 UTC | EDGAR |
| 10-Q | 0001156375-24-000149 | Jun 30, 2024 | Aug 5, 2024 | Aug 5, 2024 20:48 UTC | EDGAR |
| 10-Q | 0001156375-24-000072 | Mar 31, 2024 | May 1, 2024 | May 1, 2024 17:55 UTC | EDGAR |
| 10-K | 0001156375-24-000010 | Dec 31, 2023 | Feb 28, 2024 | Feb 28, 2024 20:24 UTC | EDGAR |
| 10-Q | 0001156375-23-000190 | Sep 30, 2023 | Nov 1, 2023 | Nov 1, 2023 18:56 UTC | EDGAR |
Direct links to SEC EDGAR. CME has additional filings available on the SEC site.
6 numbers CME GROUP INC. later changed — same XBRL tag, both filings linked.
Net Cash Provided by (Used in) Operating Activities·FY 2017
Notable restatementwas$1.8B
Revised down in a 10-K. Any P/OCF built on the original was 5.1% too low.
Net Cash Provided by (Used in) Operating Activities·Q2 2017
Notable restatementwas$823M
Revised down in a 10-Q. Any P/OCF built on the original was 5.1% too low.
Net Cash Provided by (Used in) Operating Activities·Q3 2017
Notable restatementwas$1.3B
Revised down in a 10-Q. Any P/OCF built on the original was 3.1% too low.
Net Cash Provided by (Used in) Operating Activities·Q3 2016
Notable restatementwas$1.2B
Revised up in a 10-Q. Any P/OCF built on the original was 2.2% too high.
Net Cash Provided by (Used in) Operating Activities·Q1 2016
Minor restatementwas$519.7M
Revised up in a 10-Q. Any P/OCF built on the original was 1.9% too high.
Net Cash Provided by (Used in) Operating Activities·Q2 2016
Minor restatementwas$743.2M
Revised up in a 10-Q. Any P/OCF built on the original was 1.4% too high.
CME is not the only one.
See every restatement we've found across the market — or get an alert the next time CME revises a number.
Restatements are detected by comparing every vintage of a fact across all of CME GROUP INC.'s filings back to 1993. A revision is not by itself a sign of wrongdoing — companies re-file for many legitimate reasons. This list is not exhaustive: it shows CME's most significant revisions, and a figure absent from it has not been certified as unrevised.
Who is buying and selling CME GROUP INC. — insider transactions from Forms 3/4/5/144 and institutional ownership from 13F, 13D, and 13G filings, point-in-time stamped like every other fact in the library. Traders read it as a positioning signal; risk desks read it as concentration.
No published research on CME yet.
Reports appear here as analysts publish research on this company — built with Valuein's agentic workflows on data pinned to its SEC filing. Be the first: run equity_research_brief on CME and publish the result to your public profile.
Ask about CME GROUP INC.
Continue in Workspace — cited answers on CME, a thesis you can score, or a signal on the next filing.
Open in WorkspaceGet 15 years of data
Quarterly and annual financials back to 2011 on Pro (1993 on Institutional). Point-in-time accurate, with delisted companies kept in.
View plansQuery via Python SDK
Pull data into DuckDB with 3 lines of Python. Works in Jupyter notebooks, scripts, and CI pipelines.
SDK docsConnect via MCP Server
Wire Claude, Cursor, or Codex directly to live SEC data with a single Bearer token. No scraping, no glue code.
MCP docs